A 15-year follow-up study of young adults with epilepsy found that those with uncomplicated epilepsy who were seizure-free for five years or more did as well as their siblings without epilepsy in measures of education, employment, family arrangements and driving status. Youth with complicated epilepsy had worse social outcomes and were less likely to drive, even if living without seizures. Results were published in the journal Epilepsia.
There is an uncommon risk of death that people with epilepsy and their loved ones may not know about. The risk is called sudden unexpected death in epilepsy, or SUDEP. Now the American Academy of Neurology (AAN) and the American Epilepsy Society have co-developed a new guideline on SUDEP, published in the April 24, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology, and presented at the 69th AAN Annual Meeting in Boston, April 22 to 28, 2017. The guideline is endorsed by the International Child Neurology Association. SUDEP is when someone with epilepsy who is otherwise healthy dies suddenly with no known cause.
For individuals with a severe form of epilepsy, a new study finds that the occurrence of seizures could be significantly reduced with a daily dose of cannabidiol – a chemical component of cannabis. Researchers say that cannabidiol – an active chemical in cannabis – could help to reduce seizures for patients with Lennox-Gastaut syndrome. Researchers from the Ohio State University found that individuals with Lennox-Gastaut syndrome (LGS) who took cannabidiol every day for 14 weeks saw the frequency of atonic seizures fall by more than 50 percent. Atonic seizures, also known as drop seizures, involve a sudden, brief loss of muscle tone. Study co-author Dr. Anup Patel, of the College of Medicine at Ohio State, and colleagues recently presented their findings at the American A...
Promising results from a large-scale, controlled, Phase 3 clinical study of epilepsy patients being treated with cannabidiol will be presented next week at the American Academy of Neurology’s Annual Meeting in Boston on April 25. GW Pharmaceuticals’ liquid oral formulation of cannabidiol (CBD), called Epidiolex, is one of 500 compounds found in cannabis. Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does not produce a “high” as the psychoactive component is absent. Results from the randomized, double-blind, placebo-controlled study found that almost 40 percent of people with Lennox-Gastaut syndrome (LGS) had at least a 50 percent reduction in drop seizures, compared to 15 percent taking a placebo. LGS is a severe form of epilepsy that often results in impaired intellectua...
The first refractory epilepsy patients have been implanted with Prometra II programmable infusion pumps for a clinical trial of the dose-delivery devices, according to the product’s developers, Flowonix Medical and Cerebral Therapeutics. Dan Abrams, Cerebral Therapeutics’ CEO, said the multi-center ADDRESS trial is the first study of programmable, implantable pumps delivering medication directly to the brain — what is called intracerebroventricular delivery.
Imagine a seismograph — the instrument that measures and records earthquakes and volcanic eruptions — for your brain. Except this one has a wireless link to a device implanted in your head that stops epileptic seizures at their source, halting the sudden and violent attacks before they happen. It’s not science fiction.
For people suffering with epilepsy, facing stressful events such as the war, trauma or natural disaster, or the death of a loved one, may act as a common trigger for seizures, a study has found. Epilepsy is a disorder in which nerve cell activity in the brain is disturbed, causing seizures. The findings showed that higher anxiety levels in patients with epilepsy reported stress as a seizure trigger.
Babies born to severely obese, or grade III obesity, was associated with an 82 per cent increased risk of epilepsy. A study of almost 1.5 million children has found the risk of epilepsy almost doubled among those born to severely obese mothers. Being overweight during the first trimester of pregnancy has been linked to an increased risk of childhood epilepsy. A Swedish study of almost 1.5 million babies found the risk of epilepsy almost doubled from normal-weight women to very severely obese women. Epilepsy disrupts the normal electrochemical activity of the brain resulting seizures. The cause of this debilitating and often hard-to-treat condition is poorly understood. With obesity on the rise, there is growing concern about the long-term neurological effects of children expose...
More than 50 million people of all ages suffer from epilepsy, otherwise known as seizure disorder, the fourth most common neurological disease in the world. Patients diagnosed with epilepsy often experience recurrent seizures triggered by the firing of a large collection of neurons in the brain. This ultimately generates a high-energy wave that spreads across the surface of the brain, resulting in numerous physical effects such as erratic body shaking, unconsciousness, exhaustion, and pain.
My Daughter Salina had a seizure at school the other day. He was wide awake at the time. That’s a first because until that day, he’d only ever had seizures in his sleep. I’m not sure what this means. My husband says it’s probably a one-time thing, nothing to worry about. But in our experience with epilepsy, there’s no such thing as a one-time thing.
Scientists may have found a way to improve brain connectivity. The findings may boost short-term working memory, and in the future, they may help to repair brain damage in patients with traumatic brain injury, stroke, or epilepsy.
New King’s College London research reveals how genetic defects can lead to epilepsy in children. In their new study, published in Scientific Reports and funded by Eli Lilly and Co., the researchers set out to understand how genetic defects affect electrical transmission in the brain. Understanding exactly how nerve cells are misfiring and creating seizures in children with epilepsy will allow researchers to design better, more personalised treatments for epilepsy.